Keith M Sigel, MD, PhD

Research

Locations

Center for Advanced Medicine

17 East 102nd Street, 6th Floor, New York, NY, 10029

212-659-8551

Insurance Information

Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Publications

Scopus h-index:27

Article:106

Review Article:5

Comment/Debate:1

Letter:5

Editorial:2

Recent Artifacts

• State Variation in Squamous Cell Carcinoma of the Anus Incidence and Mortality, and Association with HIV/AIDS and Smoking in the United States
• Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data
• Diagnostic features of low- and high-grade mucinous neoplasms in pancreatic cyst FNA cytology
• A Cross-Sectional Study of the Prevalence of Anal Dysplasia among Women with High-Grade Cervical, Vaginal, and Vulvar Dysplasia or Cancer: The PANDA Study
• Prophylactic feeding tube placement for squamous cell carcinoma of the head and neck
• The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: A simulation study
• Prevalence of Human Papillomavirus Infection among Women Born in the 1990s vs the 1980s and Association with HPV Vaccination in the US
• Assessment of treatment strategies for stage I non-small cell lung cancer in patients with comorbidities
• Lung cancer incidence among world trade center rescue and recovery workers
• Optimizing the use of adjuvant chemotherapy in non-small cell lung cancer patients with comorbidities

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Sigel did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.